Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17367480 | 0.87 | PRKAB2 (0.32) | MAP4K4HSD11B1CDC7OPRD1CHEK1 | |
| SCHEMBL15854085 | 0.86 | OPRM1 (0.40) | OPRD1 | |
| SCHEMBL17367492 | 0.81 | PRKAB2 (0.39) | MAP4K4 | |
| SCHEMBL19873563 | 0.79 | CASP1 (0.39) | CASP1MAP4K4CDC7P2RX7PARP1 | |
| SCHEMBL17367488 | 0.78 | CHEK1 (0.35) | CHEK1 | |
| SCHEMBL15854171 | 0.78 | MAP4K4 (0.47) | MAP4K4 | |
| SCHEMBL17367479 | 0.77 | MAPT (0.36) | MAP4K4HSD11B1 | |
| SCHEMBL17367483 | 0.77 | ACHE (0.31) | — | |
| SCHEMBL15854116 | 0.76 | PRKAB2 (0.42) | MAP4K4 | |
| SCHEMBL17367489 | 0.76 | PRKAB2 (0.40) | MAP4K4HSD11B1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | CASP1 3061/4885MAP4K4 2218/4885HSD11B1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.